Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial

摘要: Research indicates that certain antihypertensive medications alter Alzheimer's disease (AD) biomarkers in Caucasians. The renin angiotensin system (RAS) regulates blood pressure (BP) the body and brain may directly influence AD biomarkers, including amyloid-β (Aβ) neuropathology, cerebral flow (CBF), inflammatory markers. This hypothesis is supported by studies, ours, showing antihypertensives targeting RAS reduce risk slow progression of While mounting evidence supports a protective role Caucasians, this mechanism has not been explored African Americans. To assess which modify RAS, cerebrospinal fluid (CSF) Aβ, CBF, markers Americans, we are conducting an eight month, Phase Ib randomized, placebo controlled trial, enrolling 60 middle-aged (45-70 years), non-demented individuals, at for virtue parental history. Participants include normotensive treated hypertensives have never exposed to medication. randomized (1 : 1:1) gender BP medication use (yes/no) one three groups: placebo, or 20 mg, 40 mg telmisartan (Micardis), determine dose required penetrate CNS. Our overarching that, compared both doses will CNS produce salutary, dependent effects on as well CSF over months. manuscript describes trial rationale design.